Sugi Predict

Sugi Predict / Compounds / SCHEMBL272406

SCHEMBL272406

SCHEMBL272406

CC(C)(C)OC(=O)N[C@H](CO)Cc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.59
▸ PTPN1 P18031 3/20 0.58
▸ BCL2 P10415 1/20 0.57
▸ PPARA Q07869 2/20 0.50
▸ HDAC8 Q9BY41 1/20 0.50
▸ SYK P43405 1/20 0.50
▸ YAP1 P46937 2/20 0.49
▸ REN P00797 1/20 0.49
▸ APP P05067 1/20 0.49
▸ ITGB3 P05106 1/20 0.49
▸ ITGA2B P08514 1/20 0.49
▸ PPARG P37231 2/20 0.49
▸ LTA4H P09960 1/20 0.49
▸ MMP9 P14780 1/20 0.48
▸ MMP8 P22894 1/20 0.48
▸ CTSS P25774 2/20 0.48
▸ CTSL P07711 1/20 0.48
▸ CTSB P07858 1/20 0.48
▸ CTSK P43235 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL272806 1.00 ATM (0.59) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL5410539 1.00 ATM (0.59) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL15564732 0.91 RXRA (0.54) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL2617278 0.91 ATM (0.57) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL12532787 0.90 ATM (0.58) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL2617274 0.90 ATM (0.58) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL272433 0.90 ATM (0.71) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL273464 0.90 ATM (0.58) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL273465 0.90 ATM (0.58) ATMPTPN1BCL2PPARAHDAC8
SCHEMBL5888032 0.90 ATM (0.58) ATMPTPN1BCL2PPARAHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025327-A1 CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-01-26 — — US disclosed
EP-3991752-A1 CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR Hangzhou Dac Biotech Co., Ltd (CN) 2022-05-04 — — EP disclosed
WO-2021000067-A1 CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR 杭州多禧生物科技有限公司 2021-01-07 — — WO disclosed
WO-2019144805-A1 SUBSTITUTED PHENYLETHYLAMINE COMPOUND AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2019-08-01 — — WO disclosed
US-8741938-B2 Compounds that are useful for improving pharmacokinetics ABBVIE INC. (US) 2014-06-03 — — US disclosed
US-20130317071-A1 NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS ABBVIE INC (US) 2013-11-28 — — US disclosed
US-8524753-B2 Compounds that are useful for improving pharmacokinetics ABBVIE INC. (US) 2013-09-03 — — US disclosed
US-20120184559-A1 NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS ABBOTT LABORATORIES (US) 2012-07-19 — — US disclosed
US-8133892-B2 Compounds that are useful for improving pharmacokinetics ABBOTT LABORATORIES (US) 2012-03-13 — — US disclosed
US-7956220-B2 MAO-B inhibitors useful for treating obesity JENRIN DISCOVERY (US) 2011-06-07 — — US disclosed
EP-1499588-A1 MELANOCORTIN RECEPTOR LIGANDS THE PROCTER & GAMBLE COMPANY (US) 2005-01-26 — — EP disclosed
WO-2003093234-A1 MELANOCORTIN RECEPTOR LIGANDS THE PROCTER & GAMBLE COMPANY (US) 2003-11-13 — — WO disclosed
EP-0708085-B1 Antiviral ethers of aspartate protease substrate isosteres NOVARTIS AG (CH) 2002-07-17 — — EP disclosed
US-5935976-A Antiviral ethers of aspartate protease substrate isosteres NOVARTIS CORPORATION (US) 1999-08-10 — — US disclosed
US-5807891-A RETROVIRUSES NOVARTIS AG (CH) 1998-09-15 — — US disclosed
US-5663200-A CARBAMOYL PEPTIDE DERIVATIVES AS VIRICIDES CIBA-GEIGY CORPORATION (US) 1997-09-02 — — US disclosed
US-5643878-A TREATMENT OF RETROVIRAL DISEASES LIKE AIDS CIBA-GEIGY CORPORATION (US) 1997-07-01 — — US disclosed
EP-0708085-A2 Antiviral ethers of aspartate protease substrate isosteres CIBA-GEIGY AG (CH) 1996-04-24 — — EP disclosed
US-5455271-A Using aromatic amine derivitives as mosquito insecticide THE SCRIPPS RESEARCH INSTITUTE (US) 1995-10-03 — — US disclosed
EP-0618222-A2 Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid CIBA-GEIGY AG (CH) 1994-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184559-A1 NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS CYP11B1, CYP11B2, CYP7A1 ATM 4747/4885PTPN1 3084/4885BCL2 4347/4885
US-20130317071-A1 NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS CYP11B1, CYP11B2, CYP7A1 ATM 4747/4885PTPN1 3084/4885BCL2 4347/4885
US-20230025327-A1 CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING TEK, TEKT1, EPCAM ATM 3290/4885PTPN1 402/4885BCL2 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.